Workflow
XINHUA PHARM(000756)
icon
Search documents
淄博市中心血站携手新华制药开展无偿献血活动
Qi Lu Wan Bao· 2025-07-30 21:31
通讯员 宗珂 "已经献过四次血了,一点也不紧张。"环保管理部的王孟鑫今天献了400毫升血,他表示:"我们奉献的爱心, 说不定能给某位患者带去生的希望,想到这就有一种满足感,所以每次组织献血我都会来参与。"王孟鑫坦 言,他觉得自己做的事特别有意义,以后会坚持每年献血,让这份爱心继续传递下去。 张荐博 淄博报道 每一次献血都是生命的接力,传递着爱的温度,延续着生的希望。一个个血袋不断装满,既是生命之源在传 递,也是奉献担当精神在延续。 近日,山东新华制药股份有限公司积极响应号召,一分厂、二分厂、保卫部开展无偿献血活动。 在活动现场,职工们利用空余时间分批赶来,有序排队。从信息录入到静脉采血,工作人员与志愿者默契配 合,一举一动里,藏着对生命的敬畏与守护。大家用无声的行动,串联起爱心传递的纽带。 在此次无偿献血活动中,山东新华制药股份有限公司职工们的无私奉献不仅为临床患者提供了宝贵的血 液资源,也彰显了企业的凝聚力和社会责任感。据统计,在本次献血活动期间,山东新华制药股份有限公司 共有103名职工捐献热血38450毫升。 ...
世卫组织预警,全球约550万人面临感染风险!基孔肯雅热关注度高涨,三大方向涉及公司曝光!
Mei Ri Jing Ji Xin Wen· 2025-07-27 07:07
Group 1: Overview of Chikungunya Fever - Chikungunya virus is spreading globally, with 119 countries reporting cases and approximately 5.5 million people at risk of infection [1] - In Foshan, Guangdong Province, over 4,000 confirmed cases have been reported, primarily mild cases [1] Group 2: Symptoms and Treatment - Chikungunya fever is characterized by high fever and severe joint pain, particularly affecting small joints [2] - There is currently no specific treatment or widely used vaccine; management is primarily supportive, focusing on symptom relief [3] Group 3: Market Response and Company Involvement - Investors are inquiring about companies with products related to Chikungunya fever, focusing on mosquito repellent products, testing kits, and antipyretic and analgesic medications [4] - Companies like Rainbow Group, Runben Co., and Weigao Medical have reported an increase in sales of mosquito repellent products [5][6] - Pharmaceutical companies such as Renhe Pharmaceutical and Xinhua Pharmaceutical have indicated they offer products for fever and pain relief [7] Group 4: Testing Products - Companies like Kehua Bio, YHLO Biotech, and Shuoshi Bio have developed testing kits for Chikungunya virus [8] - YHLO Biotech has a rapid screening kit for Chikungunya, currently used for research purposes [8] - The market interest in these companies has led to notable stock price increases since the news of the outbreak [8]
港股医药股盘初拉升,微创医疗涨近10%
news flash· 2025-07-24 01:43
港股医药股盘初拉升,微创医疗涨近10%,复星医药(600196)、药明康德(603259)、山东新华制药 (000756)股份、石四药集团上扬。 ...
10亿元止血药红海再掀波澜:新华制药左手新药入场券,右手净利润下滑,“增收不增利”困局何解?
Hua Xia Shi Bao· 2025-07-22 14:37
Core Viewpoint - The article discusses the challenges and opportunities faced by Xinhua Pharmaceutical as it enters the competitive market for the drug Maleate Avatrombopag, highlighting its recent licensing change and the pressures on its financial performance and R&D efforts [2][12]. Financial Performance - In 2024, Xinhua Pharmaceutical reported a revenue of 8.466 billion yuan, a year-on-year increase of 4.51%, marking a historical high, but its net profit fell by 5.33% to 470 million yuan, indicating a "revenue increase without profit increase" phenomenon for the first time since 2013 [7][11]. - The company's revenue sources in 2024 included 4.072 billion yuan from formulations, 2.736 billion yuan from chemical raw materials, and 1.658 billion yuan from intermediates, with significant declines in gross margins across these categories [7][11]. - In Q1 2025, Xinhua's revenue was 2.43 billion yuan, down 1.81% year-on-year, and net profit decreased by 20.99% to 112 million yuan [8]. R&D Investment - Xinhua's total R&D investment in 2024 was 397 million yuan, a decrease of 2.23% from the previous year, with R&D expenditure accounting for 4.69% of revenue, down 0.32 percentage points [9][12]. - Despite a reduction in R&D spending, the company achieved several product approvals, including 7 products with 9 specifications receiving consistency evaluation [8][9]. Market Competition - The market for Maleate Avatrombopag is highly competitive, with 18 companies, including Fosun Pharma and others, vying for market share through price competition and channel expansion [4][5]. - The original drug, Su Ke Xin® by Fosun Pharma, has a first-mover advantage and has been included in the national medical insurance catalog, further intensifying competition [4][5]. Strategic Opportunities - Xinhua's acquisition of the Maleate Avatrombopag marketing license is seen as a potential opportunity to enhance its product portfolio in blood system disease medications and improve its competitive edge [12]. - The company needs to focus on optimizing its product structure and increasing R&D investment to maintain innovation and competitiveness in the market [12].
港股创新药概念股盘初调整,百济神州跌超5%
news flash· 2025-07-21 01:48
港股创新药概念股盘初调整,百济神州跌超5%,歌礼制药、山东新华制药(000756)股份、昭衍新药 (603127)跌超4%,君实生物、诺诚健华等股跌超3%。 ...
突然,暴涨超900%!
Market Overview - A-shares maintained a narrow fluctuation on July 16, with the Shanghai Composite Index closing at 3503.78 points, down 0.03% [1] - The Shenzhen Component Index and the ChiNext Index both fell by 0.22% to 10720.81 points and 2230.19 points, respectively [1] - The total trading volume in the Shanghai and Shenzhen markets was 146.19 billion yuan, a decrease of over 170 billion yuan from the previous day [1] Sector Performance - Financial stocks collectively declined, while the steel, non-ferrous metals, and coal sectors showed weakness [1] - The automotive supply chain stocks surged, with companies like Rongtai Co., Fuda Co., and Zhejiang Rongtai hitting the daily limit [1] - The innovative drug concept saw significant activity, with stocks like Guosheng Tang and Iwu Biotech rising approximately 16% [5][6] - The humanoid robot concept remained hot, with companies like Shangwei New Materials achieving a six-day limit increase [2][4] Notable Company Movements - Huadian New Energy, which debuted on the Shanghai main board, closed up 125.8%, reaching a market value of over 300 billion yuan at one point [1] - Weiyali, a Hong Kong-based electronic component distributor, saw its stock surge by 288% upon resuming trading, with an intraday increase exceeding 900% [1] Humanoid Robot Sector Insights - The humanoid robot industry is in its early stages, with significant growth expected in the next 3 to 5 years across various applications [4] - The current phase is described as the "dawn" of humanoid robot industrialization, with mass production and large-scale application becoming feasible [4] - Cost reduction is crucial for the widespread adoption of humanoid robots, and companies that master core component technologies are recommended for investment [4] Innovative Drug Sector Insights - The innovative drug sector experienced strong gains, with several companies hitting the daily limit [5][6] - The recent launch of the 11th batch of national drug centralized procurement is expected to impact the market, focusing on mature "old drugs" rather than innovative drugs [7] - The introduction of measures to support the high-quality development of innovative drugs indicates a growing role for commercial insurance in the healthcare system [7] Pet Economy Sector Insights - The pet economy concept gained traction, with companies like Weike Technology rising over 10% [8] - The pet food sector is viewed as a growing market with significant long-term growth potential, particularly for domestic brands [8]
第十一批药品集采启动;中生制药收购礼新|21健讯Daily
Group 1: Drug Procurement and Regulations - The National Healthcare Security Administration has initiated the 11th batch of national drug centralized procurement, with 55 varieties included in the reporting range [1] - The procurement rules emphasize principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and avoiding internal competition" [1] - Only mature "old drugs" that have been on the market for years and have expired patent protection will be included, while innovative drugs will not be part of this procurement [1] Group 2: Company Announcements and Developments - Xinhua Pharmaceutical's subsidiary received a Class III medical device registration certificate for a sterile saline solution for contact lens care [3] - Sanyou Medical announced that its spinal internal fixation connector system, JAZZSystem, received approval for market launch [4] - China National Pharmaceutical Group fully acquired Lixin Pharmaceutical for a consideration of up to $950.92 million [10] Group 3: Financial Performance - Baicheng Pharmaceutical expects a net profit of 0 to 6 million yuan for the first half of 2025, a decline of 95.53% to 100% year-on-year [6] - Kanglong Chemical anticipates a net profit of 67.92 million to 71.26 million yuan for the first half of 2025, a decrease of 36% to 39% year-on-year, despite a growth in core business [7] Group 4: Clinical Trials and Research - AstraZeneca's Baxdrostat achieved significant results in a Phase III clinical trial for patients with uncontrolled or resistant hypertension [13] - Hengrui Medicine reported positive results from a Phase III clinical trial of its GLP-1/GIP dual receptor agonist, HRS9531, showing a maximum weight reduction of 19.2% [14]
新华制药(000756) - 关于子公司产品获得三类医疗器械注册证的公告
2025-07-15 08:45
证券代码:000756 证券简称:新华制药 公告编号: 2025-44 山东新华制药股份有限公司 关于子公司产品获得三类医疗器械注册证的公告 山东新华制药股份有限公司(以下简称"公司")之子公司山东新华健康科技有限公司 近日收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》,具体情况如下: 一、医疗器械注册证的具体情况 1、产品名称:接触镜无菌生理盐水护理液 2、注册证编号:国械注准 20253161329 3、注册人名称:山东新华健康科技有限公司 4、注册人住所:山东省淄博市高新区鲁泰大道 1 甲 1 号 5、受托生产企业:山东新华制药股份有限公司 生产地址:山东省淄博市高新区兰雁大道 3 号(委托生产)、山东省淄博市高新区鲁泰 大道 1 号(委托生产)。 6、结构及组成:该产品为含有 0.9%氯化钠的无菌生理盐水溶液,由氯化钠和注射用水 组成。产品经湿热灭菌,一次性使用。货架有效期 12 个月。 7、型号、规格:10ml、20ml 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假记载、误导 性陈述或重大遗漏。 11、同类产品相关情况:根据国家药品监督管理局官网数据查询信息,截至 ...
新华制药(000756) - 2024年度A股派息实施公告
2025-07-10 10:45
证券代码:000756 证券简称:新华制药 公告编号:2025-43 山东新华制药股份有限公司 2024 年度 A 股派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述 或重大遗漏。 特别提示: ● 现金红利金额:每 10 股派发现金人民币 2.50 元(含税)。若自本派息方案披露至分配方 案实施期间公司股本总额发生变化的,公司维持每股分配比例不变,相应调整分配总额。 ● A 股股权登记日:2025 年 7 月 17 日 ● A 股除权除息日:2025 年 7 月 18 日 ● H 股股东的权益分派不适用本公告,H 股股东的权益分派安排请参见公司于香港联合交易 所有限公司及本公司网站发布的相关公告。 一、股东大会审议通过派息方案等情况 1.山东新华制药股份有限公司("本公司")2024 年度派息方案已获 2025 年 6 月 13 日召开的 2024 年度周年股东大会审议通过。 2.自本派息方案披露至实施期间公司股本总额未发生变化。 3.本次实施的派息方案与 2024 年度周年股东大会审议通过的分配方案一致。若在公司 2024 年度利润分配方案实施前,公司总股本由 ...
新华制药(000756) - 关于获得精氨酸布洛芬化学原料药上市申请批准通知书的公告
2025-06-30 09:15
证券代码:000756 证券简称:新华制药 公告编号:2025-41 山东新华制药股份有限公司 关于获得精氨酸布洛芬化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假记载、误导 性陈述或重大遗漏。 近日,山东新华制药股份有限公司("新华制药"或"本公司")收到国家药品监督管理 局核准签发的精氨酸布洛芬("本品")《化学原料药上市申请批准通知书》。现将相关情况公 告如下: 一、基本情况 原料药名称:精氨酸布洛芬 申请人:山东新华制药股份有限公司 通知书编号:2025YS00509 审批结论:根据《中华人民共和国药品管理法》及有关规定,经审查,本品符合药品注 册的有关要求,批准注册。质量标准、包装标签及生产工艺照所附执行。 二、 其他相关信息 2023 年 11 月,新华制药向国家药品监督管理局 CDE 递交精氨酸布洛芬境内生产化学原 料药上市申请注册申报资料并获受理, 2025 年 6 月获得《化学原料药上市申请批准通知 书》,审评结论为批准注册。 精氨酸布洛芬主要用于牙痛、痛经、因创伤引起的疼痛(例如:运动性损伤)、关节和 韧带痛、背痛、头痛、神经痛以及流感 ...